目的 觀察復(fù)方苦參注射液聯(lián)合注射用雷替曲塞和注射用奧沙利鉑治療晚期結(jié)腸癌的臨床療效。方法 選擇2014年1月—2015年6月襄陽(yáng)市中心醫(yī)院收治的晚期結(jié)腸癌患者78例作為研究對(duì)象,隨機(jī)分為對(duì)照組和治療組,每組各39例。對(duì)照組患者采用雷替曲塞聯(lián)合奧沙利鉑化療方案：注射用雷替曲塞3 mg/m²,溶于生理鹽水注射液100 mL,第1天靜脈滴注;注射用奧沙利鉑85 mg/m²,溶于5%葡萄糖注射液500 mL,第1天靜脈滴注。治療組患者在對(duì)照組的基礎(chǔ)上加用復(fù)方苦參注射液20 mL,溶于生理鹽水注射液100 mL中,第1～7天靜脈滴注。2周為一個(gè)周期,所有患者化療2個(gè)周期。觀察兩組的臨床近期療效和不良反應(yīng)。結(jié)果 治療后,對(duì)照組客觀緩解率為38.5%,疾病控制率為71.8%;治療組客觀緩解率為46.2%,疾病控制率為87.2%;兩組客觀緩解率和疾病控制率比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療組的惡心嘔吐、轉(zhuǎn)氨酶升高、周?chē)窠?jīng)毒性和白細(xì)胞減少的發(fā)生率均顯著低于對(duì)照組,組間比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論 復(fù)方苦參注射液聯(lián)合注射用雷替曲塞和注射用奧沙利鉑治療晚期結(jié)腸癌能具有較好的臨床近期療效,不良反應(yīng)減少,值得在臨床上進(jìn)一步推廣和應(yīng)用。

Objective To observe the clinical effect of Compound Kushen Injection combined with Raltitrexed for injection and Oxaliplatin for injection in the treatment of advanced colorectal cancer. Methods Patients (78 cases) with advanced colorectal cancer in Xiangyang Central Hospital from January 2014 to June 2015 were randomly divided into control and treatment groups, and each group had 39 cases. The patients in the control group were treated by raltitrexed combined with oxaliplatin chemotherapy. The patients in the control group were iv administered with Raltitrexed for injection in the first day, 3 mg/m² added into 100 mL normal saline. And they were also iv administered with Oxaliplatin for injection in the first day, 85 mg/m² added into 5% glucose injection (500 mL). The patients in the treatment group were iv administered with Compound Kushen Injection on the basis of control group from day 1 to day 7, 20 mL added into 0.9% normal saline (100 mL). One course of treatment included 2 weeks, and two groups were treated for two courses. The short-term efficacy and adverse reactions in two groups were observed and compared. Results After treatment, the objective response rate and disease control rate of control group were 38.5% and 71.8%, while those index of treatment group were 46.2% and 87.2%, and there were differences between two groups (P < 0.05). The incidences of nausea and vomiting, elevation of aminotransferase, peripheral nerve toxicity, and leucopenia in treatment group were significantly lower than those in the control group, and the differences were statistically significant between two groups (P < 0.05). Conclusion Compound Kushen Injection combined with Raltitrexed for injection and Oxaliplatin for injection has good clinical short-term efficacy in treatment of advanced colorectal cancer with less adverse reactions, which has a certain clinical application value.